InvestorsHub Logo
Followers 37
Posts 4190
Boards Moderated 0
Alias Born 10/18/2016

Re: None

Wednesday, 11/29/2017 11:37:46 AM

Wednesday, November 29, 2017 11:37:46 AM

Post# of 28505
Compensated Awareness Post View Disclaimer
PBIO Targets Nanoemulsions Market Through Collaboration with Phasex Corp.

Pressure BioSciences (OTCQB: PBIO) recently entered into a strategic collaboration with Phasex Corporation. The company’s goal is to combine its patented Ultra Shear Technology (“UST”) with Phasex’ Supercritical Fluid (“SCF”) processing to cultivate stable, water-soluble nanoemulsions. An article discussing this reads: “Emulsions are mixtures of two or more liquids (e.g., oils and water) that cannot be blended into each other without the addition of chemicals called surfactants. Emulsions represent an incredibly large existing market with a wide range of applications, including nutraceuticals, pharmaceuticals, cosmetics, industrial lubricants, paints and even food. Currently, most commercially-available emulsion products contain large oil droplets and high amounts of surfactants, which tend to make these macro- and micro-emulsions unstable and not suitable for human use. Conversely, scientific studies have shown that nanoemulsions (with very small oil droplet sizes) generally exhibit improved absorption, higher bioavailability, greater stability, lower surfactant levels and other clear advantages over macro- and micro-emulsions.”

To view the full article, visit http://nnw.fm/Ln0Ff

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. PBI’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug development and design, bio-therapeutics characterization, soil & plant biology, forensics, and counter-bioterror applications. Major new focal market opportunities are emerging in the use of the company’s patented, scalable, high-efficiency Ultra Shear Technology (“UST”) to create stable nanoemulsions of otherwise immiscible fluids (such as oils and water), and to prepare higher quality, homogenized, extended shelf-life or room temperature stable, low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PBIO News